Comparing Kesimpta vs Ocrelizumab
| Kesimpta (ofatumumab) | Ocrelizumab |
|
|---|
| Kesimpta (ofatumumab) | Ocrelizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Sclerosis. Ocrelizumab may also be used for purposes not listed in this medication guide. |
||||||||
| More about Kesimpta (ofatumumab) | More about Ocrelizumab | ||||||||
| Ratings & Reviews | |||||||||
|
Kesimpta has an average rating of 6.9 out of 10 from a total of 76 ratings on Drugs.com. 53% of reviewers reported a positive effect, while 18% reported a negative effect. |
Ocrelizumab has an average rating of 5.4 out of 10 from a total of 193 ratings on Drugs.com. 42% of reviewers reported a positive effect, while 42% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Kesimpta side effects |
View all Ocrelizumab side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Kesimpta prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
| Other ofatumumab brands include: Arzerra | Ocrevus | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
1476 hours |
624 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 177 drugs are known to interact with Kesimpta:
|
A total of 433 drugs are known to interact with Ocrelizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
N/A |
March 28, 2017 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ocrevus
Ocrevus (ocrelizumab) is used for MS to treat relapsing and primary progressive forms of multiple ...
Tecfidera
Tecfidera (dimethyl fumarate) is used to treat relapsing forms of multiple sclerosis. Learn about ...
Avonex
Avonex is an interferon used to treat relapsing multiple sclerosis. It is given by injection into a ...
Briumvi
Briumvi is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically ...
Betaseron
Betaseron is used to treat relapsing multiple sclerosis (MS). Learn about side effects ...
Rebif
Rebif is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically ...
Ocrevus Zunovo
Ocrevus Zunovo (ocrelizumab and hyaluronidase) is a treatment for relapsing forms of multiple ...
Extavia
Extavia is used to treat the relapsing forms of multiple sclerosis. Learn about side effects ...
Copaxone
Copaxone is used to treat relapsing forms of multiple sclerosis (MS) in adults (including ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.